MX371158B - Compuestos inhibidores de pde2. - Google Patents

Compuestos inhibidores de pde2.

Info

Publication number
MX371158B
MX371158B MX2017007380A MX2017007380A MX371158B MX 371158 B MX371158 B MX 371158B MX 2017007380 A MX2017007380 A MX 2017007380A MX 2017007380 A MX2017007380 A MX 2017007380A MX 371158 B MX371158 B MX 371158B
Authority
MX
Mexico
Prior art keywords
organic compounds
pharmaceuticals
formula
pharmaceutical compositions
relates
Prior art date
Application number
MX2017007380A
Other languages
English (en)
Other versions
MX2017007380A (es
Inventor
P Wennogle Lawrence
Li Peng
Zheng Hailin
Snyder Gretchen
Hendrick Joseph
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2017007380A publication Critical patent/MX2017007380A/es
Publication of MX371158B publication Critical patent/MX371158B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a novedosos compuestos inhibidores de PDE2 de la Fórmula I como se describe anteriormente, a su uso como productos farmacéuticos, y a composiciones farmacéuticas que los comprenden.
MX2017007380A 2014-12-06 2015-12-07 Compuestos inhibidores de pde2. MX371158B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088541P 2014-12-06 2014-12-06
PCT/US2015/064324 WO2016090380A1 (en) 2014-12-06 2015-12-07 Organic compounds

Publications (2)

Publication Number Publication Date
MX2017007380A MX2017007380A (es) 2017-10-20
MX371158B true MX371158B (es) 2020-01-20

Family

ID=56092607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007380A MX371158B (es) 2014-12-06 2015-12-07 Compuestos inhibidores de pde2.

Country Status (13)

Country Link
US (1) US10300064B2 (es)
EP (1) EP3226870B1 (es)
JP (1) JP6608934B2 (es)
KR (1) KR102557603B1 (es)
CN (1) CN107205999B (es)
AU (1) AU2015357496B2 (es)
BR (1) BR112017012007B1 (es)
CA (1) CA2969594A1 (es)
HK (2) HK1243933A1 (es)
IL (1) IL252579B (es)
MX (1) MX371158B (es)
RU (1) RU2709786C2 (es)
WO (1) WO2016090380A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7134168B6 (ja) * 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
ES2970672T3 (es) 2018-04-25 2024-05-30 Bayer Ag Nuevos compuestos de heteroaril–triazol y heteroaril–tetrazol como pesticidas
JP7516365B2 (ja) * 2018-10-23 2024-07-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603203A (en) 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
CA1251448A (en) 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
DK0379917T3 (da) 1989-01-26 1995-12-11 Bayer Ag Optisk aktive (meth)acrylsyre-drivater, deres fremstilling, deres polymerisation til optisk aktive polymere og disses anvendelse
IL98559A0 (en) 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5939419A (en) 1993-02-26 1999-08-17 Schering-Plough Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
DE19702785A1 (de) 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
KR20020038941A (ko) 1999-10-11 2002-05-24 디. 제이. 우드, 스피겔 알렌 제이 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
CN1436080A (zh) 2000-04-19 2003-08-13 利利艾科斯有限公司 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途
JP2004505054A (ja) 2000-08-01 2004-02-19 バイエル　アクチェンゲゼルシャフト 知覚を改善する医薬品としての選択的ｐｄｅ２インヒビター
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
CN1315835C (zh) 2001-08-28 2007-05-16 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
ES2429132T3 (es) 2001-08-31 2013-11-13 The Rockefeller University Atividad de fosfodiesterasa y regulación de la señalización mediada por fosfodiesterasa 1-B en el cerebro
CN1585771A (zh) 2001-11-09 2005-02-23 先灵公司 多环鸟嘌呤衍生物磷酸二酯酶v抑制剂
JP2005526502A (ja) 2002-02-21 2005-09-08 ザ ロックフェラー ユニバーシティー 脳のカルシウム依存性シグナル伝達の調節のための組成物および方法
JP2006509832A (ja) 2002-10-30 2006-03-23 ニューロ３デー サイクリックヌクレオチドホスホジエステラーゼ阻害剤、その調製及び使用
WO2004041819A1 (ja) 2002-11-06 2004-05-21 Grelan Pharmaceutical Co., Ltd. ピラゾロナフチリジン誘導体
RS20050637A (en) 2003-03-04 2007-11-15 Altana Pharma Ag., Purin-6-one-derivatives
WO2004087906A1 (en) 2003-03-31 2004-10-14 Pfizer Products Inc. Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
EA010424B1 (ru) 2003-12-16 2008-08-29 Пфайзер Продактс Инк. ПИРИДО[2,3-d]ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
WO2005083069A1 (en) * 2004-01-30 2005-09-09 Pfizer Products Inc. Pde2 crystal structures for structure based drug design
NZ553160A (en) 2004-09-02 2010-08-27 Nycomed Gmbh Anilino-substituted triazolophthalazine derivatives having PDE2 inhibitory activity
MX2007008137A (es) 2005-01-05 2007-07-19 Altana Pharma Ag Triazoloftalazinas como inhibidores de pde2.
ES2397082T3 (es) 2005-01-05 2013-03-04 Nycomed Gmbh Triazoloftalazinas como inhibidores de PDE2
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
CA2611312C (en) 2005-06-06 2013-12-03 Intra-Cellular Therapies, Inc. Organic compounds
EP1749824A1 (en) 2005-08-03 2007-02-07 Neuro3D Benzodiazepine derivatives, their preparation and the therapeutic use thereof
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
WO2007032466A1 (ja) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. 複素環化合物、その製造方法並びに用途
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
KR101222330B1 (ko) 2007-05-11 2013-01-15 화이자 인코포레이티드 아미노-헤테로시클릭 화합물
US7807629B1 (en) 2007-06-05 2010-10-05 Alcon Research, Ltd. Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma
MX2010006208A (es) 2007-12-06 2010-12-21 Intra Cellular Therapies Inc Compuestos organicos.
CN104402893A (zh) 2007-12-06 2015-03-11 武田药品工业株式会社 有机化合物
WO2010062366A1 (en) 2008-10-31 2010-06-03 Arginetix, Inc. Compositions and methods of treating endothelial disorders
US20100120763A1 (en) 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
US20100120762A1 (en) 2008-11-07 2010-05-13 Wyeth Triazine derivatives as inhibitors of phosphodiesterases
BRPI0922351A2 (pt) 2008-12-06 2018-06-05 Intracellular Therapies Inc compostos orgânicos
KR20110096032A (ko) 2008-12-06 2011-08-26 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EA201170770A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
EP2358204B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
EP2367428B1 (en) 2008-12-06 2016-04-06 Intra-Cellular Therapies, Inc. Organic compounds
CA2740398A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2011011312A1 (en) 2009-07-22 2011-01-27 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
US8858911B2 (en) 2009-10-08 2014-10-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
EP2490693A4 (en) 2009-10-19 2013-02-27 Merck Sharp & Dohme Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
CA2825699A1 (en) * 2011-02-23 2012-08-30 Thomas Allen Chappie Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
CA2836851C (en) 2011-06-07 2016-06-21 Christopher J. Helal Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
MX344600B (es) 2011-06-27 2016-12-20 Janssen Pharmaceutica Nv Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina.
EP2763989A1 (en) 2011-09-09 2014-08-13 H. Lundbeck A/S Pyridine compounds and uses thereof
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
WO2013034758A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN105246893B (zh) 2013-03-25 2017-10-27 赛诺菲 作为metap2(2型蛋氨酸氨肽酶)抑制剂的吡唑并二氮杂萘二酮衍生物
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
AU2015357496B2 (en) 2019-09-19
RU2709786C2 (ru) 2019-12-20
CN107205999B (zh) 2021-08-03
EP3226870A1 (en) 2017-10-11
IL252579B (en) 2021-05-31
WO2016090380A1 (en) 2016-06-09
RU2017123686A3 (es) 2019-07-17
US10300064B2 (en) 2019-05-28
RU2017123686A (ru) 2019-01-09
MX2017007380A (es) 2017-10-20
BR112017012007B1 (pt) 2022-11-01
AU2015357496A1 (en) 2017-07-27
US20170360792A1 (en) 2017-12-21
JP6608934B2 (ja) 2019-11-20
KR20170089000A (ko) 2017-08-02
HK1243933A1 (zh) 2018-07-27
BR112017012007A2 (pt) 2017-12-26
CN107205999A (zh) 2017-09-26
JP2017536410A (ja) 2017-12-07
EP3226870A4 (en) 2018-05-30
EP3226870B1 (en) 2019-09-25
CA2969594A1 (en) 2016-06-09
KR102557603B1 (ko) 2023-07-19
HK1243936A1 (zh) 2018-07-27
IL252579A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12016501192B1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX2017007377A (es) Compuestos organicos.
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015013042A (es) Compuestos organicos.
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MX2017008444A (es) Picolinamidas como fungicidas.
MX2017014035A (es) Formas solidas novedosas.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX2017007371A (es) Compuestos antibacterianos que tienen un amplio espectro de actividad.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PH12016501613A1 (en) Pyrazines modulators of gpr6
MX2017007380A (es) Compuestos organicos.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration